Abstract:Abstract Introduction Globally, approximately 85% of patients with chronic kidney disease (CKD) suffer from hypertension; this population is at increased risk of cardiovascular (CV) disease. Thiazide and loop diuretics are commonly used to treat hypertension and heart failure, respectively, in these patients. Diuretics alter potassium levels, which are also associated with CV outcomes. Purpose This post hoc exploratory analysis assessed the effect of the nonsteroidal mineralocorticoid receptor antagonist finerenone on CV and safety outcomes by baseline diuretic use in the FIDELITY dataset. We assessed whether the efficacy and safety of finerenone would be consistent regardless of diuretic use status at baseline, despite the effects these medications have on potassium. Methods In FIDELITY, a pooled analysis of the FIDELIO-DKD and FIGARO-DKD phase III clinical trials, eligible patients with type 2 diabetes (T2D) and CKD (urine albumin-to-creatinine ratio [UACR] ≥30–<300 mg/g and estimated glomerular filtration rate [eGFR] ≥25–≤90 ml/min/1.73 m2, or UACR ≥300–≤5000 mg/g and eGFR ≥25 ml/min/1.73 m2) were randomized 1:1 to finerenone or placebo. Patients were up-titrated to the maximum tolerated dose of renin–angiotensin system inhibitor during the run-in phase of the studies. For this analysis, patients were categorized by baseline diuretic use (yes/no for any diuretic and diuretic type) with additional on-treatment sensitivity analyses by post-baseline diuretic status. A composite CV outcome (CV death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure) assessed efficacy. Safety was assessed considering treatment-emergent adverse events. Results Of 13,026 patients, 51.5% were treated with diuretics at baseline (21.5% on loop and 24.2% on thiazide diuretics). Finerenone reduced the risk of the composite CV outcome vs. placebo and this effect was not modified by baseline diuretic use (Yes: hazard ratio [HR]: 0.86; 95% confidence interval [CI]: 0.77–0.97; No: HR: 0.86; 95% CI: 0.74–1.00; P-value for interaction = 0.95). On-treatment analysis showed concomitant diuretic use with study treatment to be mainly constant among patients during the follow-up period and sensitivity analyses revealed consistently lower incidence rates with finerenone vs. placebo on composite CV outcome across the three diuretic subgroups by corresponding on-treatment use/non-use. Hyperkalaemia rates for patients on finerenone were overall comparable by diuretic use (Yes: 13.8% vs. 5.7% for placebo; No: 14.3% vs. 8.3% for placebo). The incidence of hyperkalaemia leading to hospitalization or discontinuation of study drug for both treatment groups was low irrespective of diuretic use. Conclusion In this analysis, finerenone reduced the risk of CV outcomes in patients with CKD and T2D irrespective of baseline diuretic use. Overall, the incidence of hyperkalaemia leading to hospitalization was low across all subgroups of diuretic users.

Post-marketing safety of finerenone: a disproportionality analysis of the FDA adverse event reporting system

Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes

Real-world pharmacovigilance study of FDA adverse event reporting system events for finerenone

Effectiveness and safety of finerenone in diabetic kidney disease patients: a real-world observational study from China

Effectiveness and safety of finerenone in Chinese CKD patients without diabetes: a retrospective, real-world study

Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Early Clinical Experience of Finerenone in People with Chronic Kidney Disease and Type 2 Diabetes in Japan—A Multi-Cohort Study from the FOUNTAIN (FinerenOne mUltidatabase NeTwork for Evidence generAtIoN) Platform

Finerenone in diabetic kidney disease: A systematic review and critical appraisal

Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes

Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes: the FIDELIO-DKD Subgroup from China.

A comprehensive review of finerenone-a third-generation non-steroidal mineralocorticoid receptor antagonist

Finerenone's Impact on Major Adverse Cardiovascular Events in Chronic Kidney Disease and Type 2 Diabetes Mellitus: A Systematic Review

Tumor risks of finerenone in patients with type 2 diabetes mellitus complicated with chronic kidney disease: a meta-analysis and systematic review of randomized controlled trials

Finerenone: Efficacy of a New Nonsteroidal Mineralocorticoid Receptor Antagonist in Treatment of Patients With Chronic Kidney Disease and Type 2 Diabetes

Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis

Cardiorenal benefits of finerenone in different races and kidney function in patients with chronic kidney disease

Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective

Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus

The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis

Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials